Table 1.

Emergent symptoms in participants with or without antiparkinsonian therapy measured by MDS-UPDRS Parts IB and II according to the follow-up visit

0 to 12 Months (n of patients = 331)
MDS-UPDRS	Patients with ES (%)	Patients without ES (%)	p	STx-Yes (N = 182)		STx-No (N = 149)		Patients with ES p	ES Median p
				Patients with ES (%)	ES Median (range)	Patients with ES (%)	ES Median (range)
ES-Part IB	190 (57.4)	141 (42.6)	0.008	108 (56.8)	1 (1–4)	82 (43.2)	1 (1–6)	0.437	0.389
ES-Part II	250 (75.5)	81 (24.5)	< 0.0005	142 (56.8)	2 (1–7)	108 (43.2)	2 (1–9)	0.251	0.017
ES-Parts IB and II	288 (87.0)	43 (13.0)	< 0.0005	162 (56.3)	3 (1–11)	126 (43.8)	2 (1–12)	0.253	0.028
13 to 24 Months (n of patients = 148)
MDS-UPDRS	Patients with ES (%)	Patients without ES (%)	p	STx-Yes (N = 62)		STx-No (N = 86)		Patients with ES p	ES Median p
				Patients with ES (%)	ES Median (range)	Patients with ES (%)	ES Median (range)
ES-Part IB	62 (41.9)	86 (58.1)	0.058	25 (40.3)	1 (1–5)	37 (59.7)	1 (1–3)	0.866	0.738
ES-Part II	99 (66.9)	49 (33.1)	< 0.0005	46 (46.5)	2 (1–7)	53 (53.5)	2 (1-6)	0.116	0.024
ES-Parts IB and II	114 (77.0)	34 (23.0)	< 0.0005	49 (43.0)	3 (1–12)	65 (57.0)	2 (1-8)	0.694	0.126

STx, symptomatic treatment starting during the interval; ES, emergent symptoms.